TITLE

Oncolytic viral therapy for pancreatic cancer: current research and future directions

AUTHOR(S)
Ady, Justin W.; Heffner, Jacqueline; Klein, Elizabeth; Yuman Fong
PUB. DATE
January 2014
SOURCE
Oncolytic Virotherapy;2014, Vol. 3, p35
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The development of targeted agents and chemotherapies for pancreatic cancer has only modestly affected clinical outcome and not changed 5-year survival. Fortunately the genetic and molecular mechanisms underlying pancreatic cancer are being rapidly uncovered and are providing opportunities for novel targeted therapies. Oncolytic viral therapy is one of the most promising targeted agents for pancreatic cancer. This review will look at the current state of the development of these self-replicating nanoparticles in the treatment of pancreatic cancer.
ACCESSION #
94733461

 

Related Articles

  • Oncolytic viral therapy for pancreatic cancer: current research and future directions. Ady, Justin W.; Heffner, Jacqueline; Klein, Elizabeth; Fong, Yuman // Oncolytic Virotherapy;2014, Vol. 3, p35 

    The development of targeted agents and chemotherapies for pancreatic cancer has only modestly affected clinical outcome and not changed 5-year survival. Fortunately the genetic and molecular mechanisms underlying pancreatic cancer are being rapidly uncovered and are providing opportunities for...

  • Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advancedpancreatic cancer. Yeon-Joo Kim; Woo Jin Lee; Sang Myung Woo; Tae Hyun Kim; Sung-Sik Han; Bo Hyun Kim; Sung Ho Moon; Sang Soo Kim; Young Hwan Koh; Sang-Jae Park; Joo-Young Kim; Dae Yong Kim; Joong-Won Park // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Background: Although capecitabine has theoretical advantages in the pharmacokinetics, such as higher intratumoral and lower systemic concentration, relative to bolus 5-fluorouracil (5-FU), outcomes of chemoradiotherapy (CRT) with capecitabine or bolus 5-FU have not been directly compared in...

  • Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses. Sampath, Padma; Thorne, Steve H. // Oncolytic Virotherapy;2014, Vol. 3, p1 

    The field of oncolytic virology has made great strides in recent years. However, one key finding has been that the use of viral agents that replicate selectively in tumors is usually insufficient to achieve anything beyond small and transient responses. Instead, like most cancer therapies,...

  • SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. Tozzi, Angelo; Comito, Tiziana; Alongi, Filippo; Navarria, Pierina; Iftode, Cristina; Mancosu, Pietro; Reggiori, Giacomo; Clerici, Elena; Rimassa, Lorenza; Zerbi, Alessandro; Fogliata, Antonella; Cozzi, Luca; Tomatis, Stefano; Scorsetti, Marta // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Background: To assess the efficacy and safety of stereotactic body radiotherapy (SBRT) in patients with either unresectable locally advanced pancreatic adenocarcinoma or by locally recurrent disease after surgery. Methods: Between January 2010 and October 2011, 30 patients with unresectable or...

  • A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer. Jong Gwon Choi; Jae Hong Seo; Sang Cheul Oh; Chul Won Choi; Jun Suk Kim // Cancer Research & Treatment;Jun2012, Vol. 44 Issue 2, p127 

    Purpose The purpose of this study was to determine the efficacy and safety of treatment using gemcitabine and capecitabine for patients with advanced pancreatic cancer. Materials and Methods Patients with advanced unresectable pancreatic adenocarcinoma were enrolled in the study. Inclusion...

  • Emerging Therapeutic Targets and Agents for Pancreatic Cancer Therapy -- Where are we and where we have to go? Sebens, Susanne; Kalthoff, Holger // Anti-Cancer Agents in Medicinal Chemistry;2011, Vol. 11 Issue 5, p408 

    No abstract available.

  • Viruses and cancer. Nelson, Nancy J.; Nelson, N J // JNCI: Journal of the National Cancer Institute;10/20/99, Vol. 91 Issue 20, p1709 

    Focuses on the use of viruses to treat cancer. Historical background; Outcome of clinical trials; How the interest on viruses for cancer treatment faded.

  • Viruses as oncolytic agents: A new age for `therapeutic' viruses? Kenney, Shannon; Pagano, Joseph S. // JNCI: Journal of the National Cancer Institute;8/17/94, Vol. 86 Issue 16, p1185 

    Editorial. Discusses the potential use of viruses in lysing human cancer cells. Historical background; Types of viruses proposed as potential oncolytic agents; Advantages and disadvantages of Newcastle disease virus (NDV) and herpes simplex virus (HSV) as oncolytic agents; Pitfalls.

  • Abstracts of the 2010th Maruyama Memorial Lectures of the 79th Annual Meeting of the Medical Association of Nippon Medical School. Matsuda, Yoko // Journal of Nippon Medical School;2012, Vol. 79 Issue 1, p90 

    An abstract of a lecture on nestin-targeting therapy for the treatment of pancreatic cancer, delivered at the 79th annual meeting of the Medical Association of Nippon Medical School in Tokyo, Japan on September 3, 2011 is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics